Table 2:
Characteristics of biologics use among people with rheumatic or gastrointestinal conditions, 2018
| Characteristic | No. (%)* of people prescribed a biologic | |||
|---|---|---|---|---|
| Any biologic n = 14 089 |
Etanercept n = 3872 |
Adalimumab n = 5782 |
Infliximab n = 4558 |
|
| Sex | ||||
| Male | 6433 (45.7) | 1418 (36.6) | 2664 (46.1) | 2405 (52.8) |
| Female | 7656 (54.3) | 2454 (63.4) | 3118 (53.9) | 2153 (47.2) |
| Age, yr | ||||
| < 18 | 441 (3.1) | 51 (1.3) | 179 (3.1) | 224 (4.9) |
| 18–44 | 4310 (30.6) | 456 (11.8) | 1838 (31.8) | 2049 (45.0) |
| 45–64 | 3952 (28.1) | 1107 (28.6) | 1682 (29.1) | 1195 (26.2) |
| ≥ 65 | 5386 (38.2) | 2258 (58.3) | 2083 (36.0) | 1090 (23.9) |
| Patients treated with any innovator biologics | 12 928 (91.8) | 3256 (84.1) | 5782 (100) | 3954 (86.7) |
| New users | ||||
| Biologics | 3219 | 773 | 1708 | 767 |
| Innovator biologics | 2924 (90.8) | 305 (39.5) | 1708 (100) | 459 (59.8) |
| Prescriptions dispensed | ||||
| Biologics | 98 070 | 27 920 | 41 582 | 28 568 |
| Innovator biologics | 91 261 (93.1) | 24 270 (86.9) | 41 582 (100) | 25 409 (88.9) |
| Total cost, $ | ||||
| Biologics | 280 782 091 | 62 083 387 | 94 391 665 | 124 307 040 |
| Innovator biologics | 268 348 355 | 57 336 774 | 94 391 665 | 116 619 916 |
| Average no. biologic prescriptions/person | 7.0 | 7.2 | 7.2 | 6.3 |
| Average cost of biologics per person, $ | 19 929 | 16 034 | 16 325 | 27 272 |
*
Unless otherwise specified.